Neurodyn utilizes a portfolio approach to identify, validate, and develop bioactives for neuroprotection and the early treatment of neurological diseases. Neurodyn identifies bioactive compounds within historically-proven natural treatments with the goal of validating therapeutic candidates and ultimately developing treatments for Parkinson’s, Alzheimer’s, ALS and chronic nerve pain. Neurodyn will out-license or sell validated therapeutic candidates to pharmaceutical and consumer health players, as well as explore faster alternatives to traditional drug development, such as the US FDA Medical Food designation.

Neurodyn’s unique insight into the discovery, validation, and development of new bioactive compounds comes from a strong development capacity based on international partners with demonstrated historical knowledge of natural compounds, in-house medicinal chemistry capability, and proprietary animal models of neurological disease.

From The Blog

Clinical trial reveals improved brain function and memory after administration of Cerbella™

Study shows benefits of Neurodyn’s latest nutritional supplement for the aging brain CHARLOTTETOWN, PE, October 4, 2016. Neurodyn Life Sciences ( announced a positive outcome of a clinical trial that used gold standard cognitive assessments combined with functional Magnetic Resonance Imaging (fMRI) technology to study the effects of Cerbella™ on cognitive function. The double-blind-placebo-controlled crossover trial conducted with both male...

Neurodyn Inc. to showcase its newest innovations at international convention

(Charlottetown, PE, June 2, 2016) Neurodyn Life Sciences will take part in the BIO International Convention from June 4 to 9 in San Francisco, California. It’s the largest annual meeting and exhibition for the biotechnology industry in the world. Neurodyn will participate alongside a delegation of bioscience-based companies from Atlantic Canada, led by the Atlantic Canada Bio-Industries Alliance (ACBA)....

Neurodyn Announces Close of $1 Million Private Placement

(Charlottetown, PE, March 31, 2015) Neurodyn Life Sciences Inc. (‘Neurodyn’ or the ‘Company’), today announced it has completed a $1 million funding round from existing shareholders and a range of investors in both Canada and the US including certain US family-managed venture funds. The Company will use the funds to support development and commercial initiatives across its product line...

Read More